Holen Sie sich die Stockscreener-App
1.73
4.85%
0.08
Schlusskurs vom Vortag:
$1.65
Offen:
$1.635
24-Stunden-Volumen:
9,127
Relative Volume:
0.20
Marktkapitalisierung:
$6.32M
Einnahmen:
$3,000
Nettoeinkommen (Verlust:
$-4.53M
KGV:
-1.3961
EPS:
-1.2392
Netto-Cashflow:
$-4.69M
1W Leistung:
+2.98%
1M Leistung:
+5.49%
6M Leistung:
-33.61%
1J Leistung:
-69.22%
1-Tages-Spanne:
$1.635
$1.76
1-Wochen-Bereich:
$1.625
$1.80
52-Wochen-Spanne:
$1.16
$5.80
Pulmatrix Inc Stock (PULM) Company Profile
Firmenname
Pulmatrix Inc
Sektor
Branche
Telefon
(888) 355-4440
Adresse
945 CONCORD STREET, FRAMINGHAM, MA
Compare PULM vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PULM
Pulmatrix Inc
|
1.73 | 6.32M | 3,000 | -4.53M | -4.69M | -1.2392 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-02-09 | Eingeleitet | H.C. Wainwright | Buy |
Pulmatrix Inc Aktie (PULM) Neueste Nachrichten
PULM|Pulmatrix Inc|Price:1.640|Chg%:-0.010 - TradingKey
PULM|Pulmatrix Inc|Price:1.650|Chg%:-0.120 - TradingKey
Pulmatrix Inc (PULM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulmatrix Inc (PULM) Cash Flow - TradingKey
Pulmatrix Inc (PULM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Pulmatrix Inc (PULM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulmatrix Inc (PULM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pulmatrix, Inc. Revenue Breakdown – NASDAQ:PULM - TradingView
Pulmatrix Inc (PULM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
What Just Happened to Pulmatrix (PULM) Stock - Kavout | AI
Pulmatrix Inc. (PULM) Slips 3.89% as Stock Nears Critical Support at $1.48BPI Bear Correction - dars.gov.et
Trading the Move, Not the Narrative: (PULM) Edition - Stock Traders Daily
Halper Sadeh LLC investigates fairness of recen... - Pluang
Halper Sadeh LLC is Investigating Whether SLP, HUN, OLN, PULM are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-PULM, SLP, OLN, and HUN - The Malaysian Reserve
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN - Sahm
Pulmatrix (NASDAQ: PULM) to Merge with Eos; 75.2M Shares to Be Issued - Stock Titan
PULMPulmatrix Inc Latest SEC Filings - Finviz
PULM Q2 2025 Earnings: Continued R&D Investment Drives Net Loss as Pipeline AdvancesBanking Earnings Report - dars.gov.et
Enterprise value to EBITDA forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Pulmatrix | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsmoomoo - Moomoo
Pulmatrix (PULM) Holds Near Support After Modest DeclineStop Loss Guidance - dars.gov.et
(PULM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Pulmatrix Inc Actuals & Estimates (NASDAQ:PULM) - TradingView
Pulmatrix Inc Actuals & Estimates (LS:A3DWEE) - TradingView
Enterprise value to revenue forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Price to earnings forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Enterprise value to EBITDA forward of Pulmatrix Inc – TRADEGATE:2PU - TradingView
PULM Q2 2025 Earnings: Clinical‑Stage Biotech Reports Loss Per Share of $0.42, No RevenueEBITDA Estimate Trend - dars.gov.et
Price to earnings forward of Pulmatrix Inc – TRADEGATE:2PU - TradingView
Enterprise value to EBIT forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Pulmatrix Inc (PULM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pulmatrix Inc (PULM) Institutional Confidence - TradingKey
PULM Q2 2025 Earnings: Net Loss of $0.42 Per Share as Clinical-Stage Biotech Advances PipelineMargin Guidance - DonanımHaber
Pulmatrix Inc (PULM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulmatrix Inc (PULM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulmatrix (NASDAQ: PULM) posts 2025 loss as Cullgen merger to give Cullgen 96.4% - Stock Titan
PULM Q2 2025 Earnings: Net Loss Reported, Stock Rises as Investors Look Past Revenue AbsenceConsensus Forecast Report - newsline.com
PULM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pulmatrix Q2 2025 Earnings: Loss Per Share of $0.42 as Clinical Pipeline AdvancesEarnings Preview - newsline.com
Pulmatrix Q2 2025 Earnings: Net Loss of $0.42 per Share as Biotech Continues Pipeline DevelopmentReturn On Capital - newsline.com
PULM Q2 2025 Earnings: Clinical-Stage Biotech Reports EPS of -$0.42Revenue Inflection Point - newsline.com
Pulmatrix Inc. (PULM) Q2 2025 Earnings: Narrowing Losses Amid Clinical MilestonesCore Business Growth - newsline.com
Preclinical data: PTC-2105 boosts lean mass; Pulmatrix (NASDAQ: PULM) merger on track - Stock Titan
Pulmatrix (PULM) registers 490,910 shares for resale including 36,364 dividends - Stock Titan
PULM Q2 2025 Earnings: EPS Loss of -$0.42 on No Revenue; Stock Declines 2.27%Earnings Stability Report - dars.gov.et
Pulmatrix Stock Slides As Eos Merger Clock Starts To Matter For PULM Holders - Bez Kabli
PULM Q2 2025 Earnings: Reported Loss of $0.42 per Share as Company Advances Pipeline - dars.gov.et
PULM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Pulmatrix (PULM) Gains 1.47% as Shares Approach Key Resistance LevelIntraday Trade Ideas - The Legal Advocate
Finanzdaten der Pulmatrix Inc-Aktie (PULM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):